Nabriva Therapeutics plc
NBRVF
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.55M
Close$
Share Statistics
| Market cap | $4.55 Million |
|---|---|
| Enterprise Value | $3.29 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 1250.52% |
|---|---|
| Return on Assets | -223.87% |
| Return on Invested Capital | 1431.89% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.09 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-16.75
Average shareholder expectationRevenue Estimate
$2.25 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-16.75
Average shareholder expectationRevenue Estimate
$2.25 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nabriva Therapeutics Plc
39 employees
CEO: Theodore Schroeder Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone...